US biotech firm Halozyme Therapeutics (Nasdaq: HALO) says the US Food and Drug Administration has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase Ib/II clinical trial (S1313).
Notwithstanding, the company’s shares dipped 2.5% to $9.55 in mid-morning trading today, having slumped more than 23% to $8.90 on the original announcement of the clinical hold (The Pharma Letter April 9).
The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze